Skip to content
← Aggressive B-Cell Non-Hodgkin Lymphoma

HEALTH PROFESSIONAL · SOURCE READING

Treatment of B-Cell Lymphoblastic Lymphoma/B-Cell Acute Lymphoblastic Leukemia

Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.

Lymphoblastic lymphoma (LBL) is a very aggressive form of non-Hodgkin lymphoma, which occurs often but not exclusively in young patients. LBL is the lymphomatous manifestation of acute lymphoblastic leukemia (ALL). The treatment paradigms are based on trials for ALL because LBL and ALL are considered different manifestations of the same biological disease. LBL is commonly associated with large mediastinal masses and has a high tendency to spread to bone marrow and the central nervous system. For more information, see Acute Lymphoblastic Leukemia Treatment.

Source links and citations

Preserved source evidence · Independent clinical review pending · Not medical advice